Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness

Phase 3 Withdrawn Romark Laboratories L.C.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether nitazoxanide (NTZ) is safe and effective in treating mild or moderate COVID-19 illness in adults and adolescents at highest risk for severe outcomes. Each participant will be followed for approximately 28 days.

Timeline

Start: 2024-08
Primary completion: 2025-05
Completion: 2025-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nitazoxanide	Other / unclassified	300 mg	Oral

Trial to Evaluate Nitazoxanide for Treatment of Mild or Moderate COVID-19 in Subjects at High Risk of Severe Illness

Summary

Timeline

Drugs

Indications